ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Predicting Chemo-Radiotherapy Sensitivity With Concordant Survival Benefit in Non-Small Cell Lung Cancer via Computed Tomography Derived Radiomic Features

Liu, Yixin; Qi, Haitao; Wang, Chunni; Deng, Jiaxing; Tan, Yilong; Lin, Lin; Cui, Zhirou; Li, Jin*; Qi, Lishuang*哈尔滨工程大学test; 哈尔滨医科大学
Frontiers in Oncology2022-6-22DOI: 10.3389/fonc.2022.832343
2被引9阅读
引用收藏
分享

摘要

Background: To identify a computed tomography (CT) derived radiomic signature for the options of concurrent chemo-radiotherapy (CCR) in patients with non-small cell lung cancer (NSCLC). @@@ Methods: A total of 226 patients with NSCLC receiving CCR were enrolled from public dataset, and allocated to discovery and validation sets based on patient identification number. Using CT images of 153 patients in the discovery dataset, we pre-selected a list of radiomic features significantly associated with 5-year survival rate and adopted the least absolute shrinkage and selection operator regression to establish a predictive radiomic signature for CCR treatment. We performed transcriptomic analyzes of the signature, and evaluated its association with molecular lesions and immune landscapes in a dataset with matched CT images and transcriptome data. Furthermore, we identified CCR resistant genes positively correlated with resistant scores of radiomic signature and screened essential resistant genes for NSCLC using genome-scale CRIPSR data. Finally, we combined DrugBank and Genomics of Drug Sensitivity in Cancer databases to excavate candidate therapeutic agents for patients with CCR resistance, and validated them using the Connectivity Map dataset. @@@ Results: The radiomic signature consisting of nine features was established, and then validated in the dataset of 73 patients receiving CCR log-rank P = 0.0005, which could distinguish patients into resistance and sensitivity groups, respectively, with significantly different 5-year survival rate. Furthermore, the novel proposed radiomic nomogram significantly improved the predictive performance (concordance indexes) of clinicopathological factors. Transcriptomic analyzes linked our signature with important tumor biological processes (e.g. glycolysis/glucoseogenesis, ribosome). Then, we identified 36 essential resistant genes, and constructed a gene-agent network including 10 essential resistant genes and 35 candidate therapeutic agents, and excavated AT-7519 as the therapeutic agent for patients with CCR resistance. The therapeutic efficacy of AT-7519 was validated that significantly more resistant genes were down-regulated induced by AT-7519, and the degree gradually increased with the enhanced doses. @@@ Conclusions: This study illustrated that radiomic signature could non-invasively predict therapeutic efficacy of patients with NSCLC receiving CCR, and indicated that patients with CCR resistance might benefit from AT-7519 or CCR treatment combined with AT-7519.

学科与关键词

关键词
computed tomographynon-small cell lung cancerconcurrent chemo-radiotherapyradiomic signaturecandidate therapeutic agents
相关
加载中…
  • CT-derived radiomic analysis for predicting the survival rate of patients with non-small cell lung cancer receiving radiotherapy
    Zhang, Nannan; Zhang, Xinxin; Li, Junheng; Ren, Jie; Li, Luyang; Dong, Wenlei*; Liu, Yixin*PHYSICA MEDICA, 2023, 107: 102546.被引 2
  • Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study
    Wu, Shaowei; Zhan, Weijie; Liu, Lan; Xie, Daipeng; Yao, Lintong; Yao, Henian; Liao, Guoqing; Huang, Luyu; Zhou, Yubo; You, Peimeng; Huang, Zekai; Li, Qiaxuan; Xu, Bin; Wang, Siyun; Wang, Guangyi; Zhang, Dong-Kun; Qiao, Guibin; Chan, Lawrence Wing-Chi; Lanuti, Michael; Zhou, Haiyu*Journal for ImmunoTherapy of Cancer, 2023, 11(10): e007369.
  • Preoperative computed tomography-based tumoral radiomic features prediction for overall survival in resectable non-small cell lung cancer
    Peng, Bo; Wang, Kaiyu; Xu, Ran; Guo, Congying; Lu, Tong; Li, Yongchao; Wang, Yiqiao; Wang, Chenghao; Chang, Xiaoyan; Shen, Zhiping; Shi, Jiaxin; Xu, Chengyu; Zhang, Linyou*Frontiers in Oncology, 2023, 13: 1131816.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-06-22
卷期
第 12 卷
页码
832343
DOI
10.3389/fonc.2022.832343
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81872396, 61773134]; National Undergraduate Innovation and Entrepreneurship Training Program [202110226018]

作者

  • L

    Liu, Yixin (第一作者)

    harbin engn univ · harbin med univ

  • Q

    Qi, Haitao

    harbin med univ

查看全部 9 位作者收起作者
  • W

    Wang, Chunni

    harbin med univ

  • D

    Deng, Jiaxing

    harbin med univ

  • T

    Tan, Yilong

    harbin med univ

  • L

    Lin, Lin

    harbin med univ

  • C

    Cui, Zhirou

    harbin med univ

  • L

    Li, Jin (通讯)

    harbin engn univ

  • Q

    Qi, Lishuang (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417